Compare PHR & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHR | PLSE |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2019 | 2016 |
| Metric | PHR | PLSE |
|---|---|---|
| Price | $15.78 | $14.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 1 |
| Target Price | ★ $31.24 | $22.00 |
| AVG Volume (30 Days) | ★ 954.5K | 163.6K |
| Earning Date | 03-11-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $463,205,000.00 | $86,000.00 |
| Revenue This Year | $15.57 | N/A |
| Revenue Next Year | $15.08 | $1,002.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.33 | N/A |
| 52 Week Low | $15.40 | $12.56 |
| 52 Week High | $32.76 | $25.00 |
| Indicator | PHR | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 55.07 |
| Support Level | $15.40 | $13.82 |
| Resistance Level | $16.58 | $14.79 |
| Average True Range (ATR) | 0.61 | 0.80 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 16.59 | 66.67 |
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.